Program
Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505
Also written as “B1962” and “AP505”.
Its studies are mostly in Colorectal Neoplasms · Triple Negative Breast Neoplasms · Neoplasms, led by 2 companies.
Drug pageAnti-PD-L1/Anti-VEGF Bispecific Antibody AP505: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Groupits history only | 33 open or running | phase 2since Nov 28, 2024 | Nov 9, 2022 | Jan 1, 2027phase 2 · NCT06838546 |
| AP Biosciencesits history only | 11 open or running | phase 1since Nov 22, 2024 | Nov 22, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2022First study: phase 1 study in NeoplasmsNew to China Resources Pharmaceutical GroupChina Resources Pharmaceutical Group · NCT05650385 · 68 planned · China
- Nov 22, 2024AP Biosciences’ first study: phase 1 study in Advanced Solid TumorsNew to AP BiosciencesAP Biosciences · NCT06723964 · 35 enrolled · Taiwan
- Nov 28, 2024Phase 2 study in Triple Negative Breast NeoplasmsChina Resources Pharmaceutical Group · NCT06724263 · 120 planned · China
- Feb 17, 2025Phase 2 study in Advanced Colorectal CancerChina Resources Pharmaceutical Group · NCT06838546 · 80 planned · China
Ahead
- Jan 1, 2027Primary completion: phase 2 study in Advanced Colorectal CancerChina Resources Pharmaceutical Group · NCT06838546
TargetBeta
“A bispecific antibody composed of an immunoglobulin G1 (IgG1) monoclonal antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06838546Advanced Colorectal Cancer · China | 2 | Not yet recruiting | China Resources Pharmaceutical Group | Jan 1, 2027 | 80 |
| NCT06724263Triple Negative Breast Neoplasms · China | 2 | Not yet recruiting | China Resources Pharmaceutical Group | Aug 2026 | 120 |
| NCT06723964Advanced Solid Tumors · Taiwan | 1 | Active, not recruiting | AP Biosciences | Oct 31, 2024 | 35 |
| NCT05650385Neoplasms · China | 1 | Not yet recruiting | China Resources Pharmaceutical Group | Dec 2023 | 68 |
How it is read
Names in the registry
- “B1962”, 3 entries
- “AP505”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.